Switch theme
Sign up to access all valuation multiples
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatments of severe pain in conditions such as osteoarthritis.
2012
11
LTM Revenue $0.9M
LTM EBITDA -$0.6M
$26.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AlzeCure Pharma has a last 12-month revenue (LTM) of $0.9M and a last 12-month EBITDA of -$0.6M.
In the most recent fiscal year, AlzeCure Pharma achieved revenue of n/a and an EBITDA of -$3.6M.
AlzeCure Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AlzeCure Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$0.6M | XXX | -$3.6M | XXX | XXX | XXX |
| EBITDA Margin | -71% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$1.9M | XXX | -$3.7M | XXX | XXX | XXX |
| EBIT Margin | -218% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$0.5M | XXX | -$3.6M | XXX | XXX | XXX |
| Net Margin | -63% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AlzeCure Pharma's stock price is SEK 3 (or $0).
AlzeCure Pharma has current market cap of SEK 275M (or $28.4M), and EV of SEK 255M (or $26.3M).
See AlzeCure Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.3M | $28.4M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AlzeCure Pharma has market cap of $28.4M and EV of $26.3M.
AlzeCure Pharma's trades at n/a EV/Revenue multiple, and -7.3x EV/EBITDA.
Equity research analysts estimate AlzeCure Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AlzeCure Pharma has a P/E ratio of -52.5x.
See valuation multiples for AlzeCure Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28.4M | XXX | $28.4M | XXX | XXX | XXX |
| EV (current) | $26.3M | XXX | $26.3M | XXX | XXX | XXX |
| EV/Revenue | 30.8x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -43.6x | XXX | -7.3x | XXX | XXX | XXX |
| EV/EBIT | -14.1x | XXX | -7.0x | XXX | XXX | XXX |
| EV/Gross Profit | 30.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -52.5x | XXX | -7.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlzeCure Pharma's last 12 month revenue growth is 42%
AlzeCure Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.3M for the same period.
AlzeCure Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AlzeCure Pharma's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AlzeCure Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -71% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 236% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AlzeCure Pharma acquired XXX companies to date.
Last acquisition by AlzeCure Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . AlzeCure Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AlzeCure Pharma founded? | AlzeCure Pharma was founded in 2012. |
| Where is AlzeCure Pharma headquartered? | AlzeCure Pharma is headquartered in Sweden. |
| How many employees does AlzeCure Pharma have? | As of today, AlzeCure Pharma has 11 employees. |
| Is AlzeCure Pharma publicy listed? | Yes, AlzeCure Pharma is a public company listed on STO. |
| What is the stock symbol of AlzeCure Pharma? | AlzeCure Pharma trades under ALZCUR ticker. |
| When did AlzeCure Pharma go public? | AlzeCure Pharma went public in 2018. |
| Who are competitors of AlzeCure Pharma? | Similar companies to AlzeCure Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of AlzeCure Pharma? | AlzeCure Pharma's current market cap is $28.4M |
| What is the current revenue of AlzeCure Pharma? | AlzeCure Pharma's last 12 months revenue is $0.9M. |
| What is the current revenue growth of AlzeCure Pharma? | AlzeCure Pharma revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of AlzeCure Pharma? | Current revenue multiple of AlzeCure Pharma is 30.8x. |
| Is AlzeCure Pharma profitable? | Yes, AlzeCure Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AlzeCure Pharma? | AlzeCure Pharma's last 12 months EBITDA is -$0.6M. |
| What is AlzeCure Pharma's EBITDA margin? | AlzeCure Pharma's last 12 months EBITDA margin is -71%. |
| What is the current EV/EBITDA multiple of AlzeCure Pharma? | Current EBITDA multiple of AlzeCure Pharma is -43.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
